b
Laboratory of Rare Lung Diseases
3e 3b 3dMichael W. Sims
6c 16
19
1
49
2
23
1b
1d
18
2d
74
1d
2 29
1d
25
Michael W. Sims
78
74
Associate Professor of Clinical Medicine (Pulmonary, Allergy and Critical Care)
28
80
3
5f
Clinical Director, COPD Program, University of Pennsylvania Health System
77
Lead Physician, COPD Cavalry Program, University of Pennsylvania
11
Department: Medicine
4
1
b
1d
46
Contact information
67
4
3
3
3
2
4
b
1f
67
3737 Market Street, 10th floor
Philadelphia, PA 19104
26
Philadelphia, PA 19104
2e
Office: 215-662-8766
32 Fax: 215-243-3265
24
97
32 Fax: 215-243-3265
24
Email:
michael.sims@uphs.upenn.edu
12
michael.sims@uphs.upenn.edu
13
Education:
21 7 BA 20 (Music; Pre-Medicine) c
36 Franklin and Marshall College, 1993.
21 7 MD 15 (Medicine) c
46 University of Pennsylvania School of Medicine, 1998.
21 9 MSCE 37 (Master of Science in Clinical Epidemiology) c
67 Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 2006.
c
3
3
3
3
90
Permanent link21 7 BA 20 (Music; Pre-Medicine) c
36 Franklin and Marshall College, 1993.
21 7 MD 15 (Medicine) c
46 University of Pennsylvania School of Medicine, 1998.
21 9 MSCE 37 (Master of Science in Clinical Epidemiology) c
67 Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 2006.
c
2 29
21
1e
1d
24
5e
65
16 COPD/Emphysema
30 Lung Volume Reduction Surgery Evaluation
2a Procedural Treatments for Emphysema
1a 29
27
Description of Research Expertise
321 During fellowship training, Dr. Sims completed a Masters Degree in Clinical Epidemiology at the University of Pennsylvania, studying the functional consequences of secondary pulmonary hypertension in patients with severe COPD. After completing his fellowship training, he went on to be the principal investigator of a K23 award from the NIH/NHLBI investigating surfactant protein D as a modulator of lung inflammation and COPD pathogenesis. In addition, he has been actively involved in multiple clinical and translational studies of biomarkers and novel therapies for COPD as well as bronchoscopic treatments for severe emphysema. In 2013, Dr. Sims redirected his career to focus on the clinical care of advanced COPD, and now serves as the Clinical Director of the Penn COPD Program.65
Description of Clinical Expertise
24 Adult Critical Care16 COPD/Emphysema
30 Lung Volume Reduction Surgery Evaluation
2a Procedural Treatments for Emphysema
1a 29
23
202 Jacob A. Martin, Andrew Crane-Droesch, Folasade C. Lapite, Joseph C. Puhl, Tyler E. Kmiec, Jasmine A. Silvestri, Lyle H. Ungar, Bruce P. Kinosian, Blanca E. Himes, Rebecca A. Hubbard, Joshua M. Diamond, Vivek Ahya, Michael W. Sims, Scott D. Halpern, Gary E. Weissman: Development and validation of a prediction model for actionable aspects of frailty in the text of clinicians' encounter notes. J Am Med Inform Assoc 29(1): 109-19, Dec 2021.
16b Atochina-Vasserman EN, Guo C-J, Abramova E, Golden TN, Sims MW, James ML, Beers MF, Gow AJ, Krymskaya VP: Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology 53(1): 96-104, July 2015.
119 Sims MW: Acute respiratory failure due to chronic obstructive pulmonary disease. The Intensive Care Unit Manual, 2nd Edition. Lanken PN, Manaker S, Kohl BA, Hanson III CW (eds.). Elsevier, Page: 715-22, 2014.
156 Lipson DA, Holsclaw D, Imbesi G, Ferrin M, Sims MW, Miller S, Tal-Singer R, Hadjiliadis D: Evidence of Elevated CXCR2 Agonists in Stable Outpatients with Cystic Fibrosis Compared with Healthy Controls. Journal of Pulmonary and Respiratory Medicine 3(3): 149, June 2013.
c2 Sims MW: Bullous lung disease. Clinical Decision Support in Medicine - Epub. Reines L, Grippi M, Kotloff RM (eds.). 2013.
da Sims MW: Aerosol therapy for obstructive lung diseases: device selection and practice management issues. Chest 140(3): 781–788, September 2011.
f5 Sims MW, Panettieri RA: Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of COPD 6(1): 457-66, September 2011.
1ce Sims MW, Beers MF, Ahya VN, Kawut SM, Sims KD, Lederer DJ, Palmer SM, Wille K, Lama V, Shah PD, Orens JB, Bhorade S, Crespo M, Weinacker A, Demissie E, Bellamy S, Christie JD, and Ware LB for the Lung Transplant Outcomes Group: Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis. Chest 140(2): 489-96, August 2011.
187 Amrani Y, Syed F, Huang C, Li K, Liu V, Jain D, Keslacy S, Sims MW, Baidouri H, Cooper PR, Zhao H, Siddiqui S, Brightling CE, Griswold D, Li L, Panettieri RA: Expression and activation of the oxytocin receptor in airway smooth muscle cells: Regulation by TNFalpha and IL-13. Respiratory Research 11(1): 104, July 2010.
2c
7
1d
1f
Selected Publications
1c7 Gary E Weissman, Jasmine A Silvestri, Folasade Lapite, Isabelle S Mullen, Nicholas S Bishop, Tyler Kmiec, Amy Summer, Michael W Sims, Vivek N Ahya, Shreya Kangovi, Tamar A Klaiman, Julia E Szymczak, Joanna L Hart: A Qualitative Study Identifying the Potential Risk Mechanisms Leading to Hospitalization for Patients With Chronic Lung Disease. Chest Pulmonary 2(3): 100060, Sep 2024.202 Jacob A. Martin, Andrew Crane-Droesch, Folasade C. Lapite, Joseph C. Puhl, Tyler E. Kmiec, Jasmine A. Silvestri, Lyle H. Ungar, Bruce P. Kinosian, Blanca E. Himes, Rebecca A. Hubbard, Joshua M. Diamond, Vivek Ahya, Michael W. Sims, Scott D. Halpern, Gary E. Weissman: Development and validation of a prediction model for actionable aspects of frailty in the text of clinicians' encounter notes. J Am Med Inform Assoc 29(1): 109-19, Dec 2021.
16b Atochina-Vasserman EN, Guo C-J, Abramova E, Golden TN, Sims MW, James ML, Beers MF, Gow AJ, Krymskaya VP: Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology 53(1): 96-104, July 2015.
119 Sims MW: Acute respiratory failure due to chronic obstructive pulmonary disease. The Intensive Care Unit Manual, 2nd Edition. Lanken PN, Manaker S, Kohl BA, Hanson III CW (eds.). Elsevier, Page: 715-22, 2014.
156 Lipson DA, Holsclaw D, Imbesi G, Ferrin M, Sims MW, Miller S, Tal-Singer R, Hadjiliadis D: Evidence of Elevated CXCR2 Agonists in Stable Outpatients with Cystic Fibrosis Compared with Healthy Controls. Journal of Pulmonary and Respiratory Medicine 3(3): 149, June 2013.
c2 Sims MW: Bullous lung disease. Clinical Decision Support in Medicine - Epub. Reines L, Grippi M, Kotloff RM (eds.). 2013.
da Sims MW: Aerosol therapy for obstructive lung diseases: device selection and practice management issues. Chest 140(3): 781–788, September 2011.
f5 Sims MW, Panettieri RA: Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of COPD 6(1): 457-66, September 2011.
1ce Sims MW, Beers MF, Ahya VN, Kawut SM, Sims KD, Lederer DJ, Palmer SM, Wille K, Lama V, Shah PD, Orens JB, Bhorade S, Crespo M, Weinacker A, Demissie E, Bellamy S, Christie JD, and Ware LB for the Lung Transplant Outcomes Group: Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis. Chest 140(2): 489-96, August 2011.
187 Amrani Y, Syed F, Huang C, Li K, Liu V, Jain D, Keslacy S, Sims MW, Baidouri H, Cooper PR, Zhao H, Siddiqui S, Brightling CE, Griswold D, Li L, Panettieri RA: Expression and activation of the oxytocin receptor in airway smooth muscle cells: Regulation by TNFalpha and IL-13. Respiratory Research 11(1): 104, July 2010.
2c